Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Hemostemix Inc. (V:HEM)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for HEM within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 30, 2022 10:02 ET
Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") thanks Mr. Neim Malo, founder of Beefstro's, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s).
Read full article
Nov 17, 2022 08:29 ET
Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0) now available on YouTube.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.39
--
--
Price to Sales - TTM
--
2.80
4.47
Price to Book - most recent quarter
--
1.95
1.67
Price to Cash Flow per share - TTM
--
4.72
9.11
Price to Free Cash Flow per share - TTM
--
3.88
12.54
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 30, 2022618-6,793
Nov 15, 20227,411-79,501
Oct 31, 202286,91234,500
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The principal business is to develop, manufacture and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by treatments. It is focused on developing and commercializing autologous cell therapy to treat ischemic diseases. Its technology includes methods for collecting the synergetic cell population and manufacturing (isolation, enrichment and differentiation) a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. ACP-01, its clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia (CLI). ACP-01 is in a Phase II clinical trial in Canada and the United States. The Company's wholly owned subsidiaries include Kwalata Trading Limited and Hemostemix Ltd.

See business summary

 

Twitter

Search (past week) for $HEM.CA HEM.V